These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30274909)

  • 1. Verteporfin as a Medical Treatment in Peyronie's Disease.
    Mohede DCJ; de Jong IJ; Bank RA; van Driel MF
    Sex Med; 2018 Dec; 6(4):302-308. PubMed ID: 30274909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verteporfin ameliorates fibrotic aspects of Dupuytren's disease nodular fibroblasts irrespective the activation state of the cells.
    Puerta Cavanzo N; Riesmeijer SA; Holt-Kedde IL; Werker PMN; Piersma B; Olinga P; Bank RA
    Sci Rep; 2022 Aug; 12(1):13940. PubMed ID: 35977978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
    Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
    J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.
    Milenkovic U; Ilg MM; Zuccato C; Ramazani Y; De Ridder D; Albersen M
    BJU Int; 2019 Apr; 123(4):703-715. PubMed ID: 30536599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
    Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
    Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Management Options for Patients With Atypical Peyronie's Disease.
    Yafi FA; Hatzichristodoulou G; DeLay KJ; Hellstrom WJ
    Sex Med Rev; 2017 Apr; 5(2):211-221. PubMed ID: 27544298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
    Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease.
    Milenkovic U; Ilg MM; Cellek S; Albersen M
    Sex Med Rev; 2019 Oct; 7(4):679-689. PubMed ID: 30962046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
    Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts.
    Shi-Wen X; Racanelli M; Ali A; Simon A; Quesnel K; Stratton RJ; Leask A
    J Cell Commun Signal; 2021 Mar; 15(1):71-80. PubMed ID: 33398723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methylprednisolone mediates YAP/TAZ-TEAD in vocal fold fibroblasts with macrophages.
    Nakamura R; Bing R; Gartling GJ; Garabedian MJ; Branski RC
    Res Sq; 2024 Jul; ():. PubMed ID: 39070624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis.
    Futakuchi A; Inoue T; Wei FY; Inoue-Mochita M; Fujimoto T; Tomizawa K; Tanihara H
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3069-3078. PubMed ID: 30025139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Management Options for Active-Phase Peyronie's Disease.
    Brimley SC; Yafi FA; Greenberg J; Hellstrom WJG; Tue Nguyen HM; Hatzichristodoulou G
    Sex Med Rev; 2019 Apr; 7(2):329-337. PubMed ID: 30503796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polydatin attenuates tubulointerstitial fibrosis in diabetic kidney disease by inhibiting YAP expression and nuclear translocation.
    He M; Feng L; Chen Y; Gao B; Du Y; Zhou L; Li F; Liu H
    Front Physiol; 2022; 13():927794. PubMed ID: 36277194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease.
    Haag SM; Hauck EW; Szardening-Kirchner C; Diemer T; Cha ES; Weidner W; Eickelberg O
    Eur Urol; 2007 Jan; 51(1):255-61. PubMed ID: 16782264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic fibroblast growth factor expression in Peyronie's disease.
    Mulhall JP; Thom J; Lubrano T; Shankey TV
    J Urol; 2001 Feb; 165(2):419-23. PubMed ID: 11176387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
    Levine LA; Cuzin B; Mark S; Gelbard MK; Jones NA; Liu G; Kaufman GJ; Tursi JP; Ralph DJ
    J Sex Med; 2015 Jan; 12(1):248-58. PubMed ID: 25388099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
    Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition.
    Shi G; Wang H; Han H; Gan J; Wang H
    Exp Ther Med; 2018 Sep; 16(3):2751-2755. PubMed ID: 30210616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.